GET DAILY SIGNALSRevvity (RVTY) Reports Solid Q3 Results with +4.3% Revenue Growth and +17% EPS Rise
Key Takeaways
- Revvity reported third-quarter 2026 revenue of $728.9 million, up 4.3% year over year, with pro forma organic growth of 7%.
- Adjusted earnings per share (EPS) rose roughly 17% to $1.38, beating consensus estimates near $1.30.
- The Life Sciences segment led results with 9% organic growth, fueled by improving pharmaceutical and biotech demand.
- Diagnostics grew 5% organically on a pro forma basis, excluding the China immunodiagnostics business slated for divestiture.
- Management raised full-year 2026 adjusted EPS guidance to a range of $5.40 to $5.45 and lifted its revenue outlook to about $2.86 billion.
Putting the Earnings in Context
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. Its quarterly earnings serve as a barometer for two important end markets: pharmaceutical and biotech research spending, and specialty clinical diagnostics. After several quarters shaped by soft academic demand and pronounced China headwinds, this report was closely watched for signs of a genuine recovery in customer funding. Investors were also monitoring how the company's push into AI-enabled software and a planned exit from its China immunodiagnostics business would reshape growth and margins. Strong life sciences momentum and an upgraded full-year outlook signal that the company's transformation strategy is beginning to translate into financial results. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter of fiscal 2026, RVTY reported revenue of $728.9 million, an increase of 4.3% from the prior-year period and ahead of consensus estimates near $695 million. On a pro forma basis, which adjusts for the pending divestiture of the China immunodiagnostics business, revenue was $709.6 million, up 7.4%, with organic growth of 7%.
Adjusted EPS from continuing operations came in at $1.38, up about 17% from $1.18 a year ago and above the consensus estimate of roughly $1.30. On a generally accepted accounting principles (GAAP) basis, EPS from continuing operations was $0.56, compared with $0.41 in the year-ago quarter.
By segment, Life Sciences revenue rose 10.7% to $379.6 million, with 9% organic growth driven by improving pharma, biotech, and academic demand. Diagnostics revenue declined 1.9% on a reported basis to $349.3 million, but grew 4% on a pro forma basis and 5% organically once the China immunodiagnostics business was excluded. Adjusted operating margin expanded to 28.7%, or 29.4% on a pro forma basis, reflecting higher volumes and operational efficiency.
Management raised its full-year 2026 outlook to adjusted EPS of $5.40 to $5.45, up from $5.30 to $5.40, with revenue of about $2.86 billion and roughly 5% pro forma organic growth.
Market Reaction and Investor Sentiment
Investors responded enthusiastically to the results, sending RVTY shares sharply higher intraday and toward a fresh 52-week high. The market's positive reaction reflected the combination of a top-and-bottom-line beat, broad-based organic growth, and an upward revision to full-year guidance. Sentiment was further supported by evidence that pharmaceutical and biotech spending is normalizing and that AI-related demand is broadening beyond the company's high-content screening franchise. The decision to divest the China immunodiagnostics business was also viewed favorably, as it reduces exposure to a persistently weak end market while improving the reported margin profile over time.
Forward Outlook and Key Factors to Monitor
Revvity's upgraded 2026 guidance signals confidence that its growth and efficiency initiatives are taking hold, but several factors will shape the path ahead. Management noted that fourth-quarter growth may moderate somewhat, partly because some reagent bulk orders shifted into the third quarter and Signals Software growth is expected to ease from high-teens into the mid-teens range.
Investors will want to track the timing and execution of the planned China immunodiagnostics divestiture, which is subject to regulatory approvals and customary closing conditions. The completion of that transaction would simplify the company's reporting structure and lift its blended margin profile. Sustained recovery in pharmaceutical, biotech, and academic funding remains a central driver, as does the trajectory of AI-enabled product adoption across the portfolio.
On the diagnostics side, reproductive health demand and the rollout of the company's type 1 diabetes screening assay in Europe are worth monitoring, even as weak Chinese birth rates continue to weigh on that franchise. Margin expansion, free cash flow generation, and the pace of capital deployment will also remain important indicators of how effectively management converts improving demand into durable earnings growth. From what I see, this is important because it shows the company is adapting to shifting market conditions.
Exploring AI Tools for Earnings Analysis
In my view, tools like Tickeron’s AI Screener can add real value when reviewing quarterly results. I use it to quickly filter for stocks showing similar earnings momentum, technical patterns, and industry trends, which helps put a single company’s performance into broader context without spending hours on manual research. It has become a regular part of how I cross-check ideas before forming a fuller picture.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for RVTY turns positive, indicating new upward trend
RVTY saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 61 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where RVTY advanced for three days, in 200 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 122 of 181 cases where RVTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for RVTY moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 24 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 68 cases where RVTY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for RVTY turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 33 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVTY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
RVTY broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. RVTY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.340) is normal, around the industry mean (65.876). P/E Ratio (72.885) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (0.734) is also within normal values, averaging (3.473). Dividend Yield (0.002) settles around the average of (0.002) among similar stocks. P/S Ratio (5.656) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVTY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of analytical instruments
Industry MedicalSpecialties
Advertisement